|
2026 Journal Article [177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trialChan, David L, Sjoquist, Katrin Marie, Ransom, David Turner, Wyld, David, Wilson, Kate, Gebski, Val, Murray, James, Kiberu, Andrew Ddembe, Burge, Matthew E., Macdonald, William, Roach, Paul, Pattison, David A, Butler, Patrick, Price, Timothy Jay, Michael, Michael, Lawrence, Benjamin James, Bailey, Dale L., Leyden, John, Leyden, Simone, Zalcberg, John Raymond, Turner, J. Harvey and Pavlakis, Nick (2026). [177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial. European Journal of Cancer, 241 116781, 116781. doi: 10.1016/j.ejca.2026.116781 |
|
2026 Journal Article A qualitative approach to understanding quality symptom management in routine oncology outpatient care: phase 1 of the symptom pathways projectRoberts, Natasha A., Maresco-Pennisi, Diane, Boyte, Francesca, Smith, Michael, Jacmon, Helene and Wyld, David (2026). A qualitative approach to understanding quality symptom management in routine oncology outpatient care: phase 1 of the symptom pathways project. Supportive Care in Cancer, 34 (4) 402. doi: 10.1007/s00520-026-10541-0 |
|
2026 Journal Article P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)Mak, Blossom, Tran, Ben, Thomas, Hayley, Walker, Rick, Pashankar, Farzana, Feldman, Darren R., Hansen, Aaron Richard, Huddart, Robert A., Dunwoodie, Elaine, Wheater, Matthew, Stevanovic, Amanda Gwendolyn, Mazhar, Danish, Lawrence, Nicola Jane, Birtle, Alison Jane, Oladipo, Olabode, Wyld, David, Balagtas, Jay Michael S., Stockler, Martin R. and Grimison, Peter S. (2026). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs). Journal of Clinical Oncology, 44 (7_suppl), TPS623-TPS623. doi: 10.1200/JCO.2026.44.7_suppl.TPS623 |
|
2026 Journal Article Results from the Phase 1b Dose Escalation of 212Pb-ADVC001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and novel 212Pb PET Clinical ImagingHansen, Aaron R, Ngai, Stanley, Goh, Jeffrey C, Wyld, David, Gan, Chun Loo, Katchel, Loren, O'Mahoney, Eoin, Griffiths, Matthew R, Brady, Jasmine, Kuchel, Anna, Latter, Melissa, Mason, Robert, Santoro, Paola, Crumbaker, Megan, Baronet, Meghan C, Grace, Reilly, Brilhante, Joana, Rose, Stephen, Kryza, Thomas, Kuan, Kevin, Wiegert, Erol, Karmann, Anna and Pattison, David A (2026). Results from the Phase 1b Dose Escalation of 212Pb-ADVC001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and novel 212Pb PET Clinical Imaging. Journal of Medical Imaging and Radiation Sciences, 57 (2) 102292, 102292. doi: 10.1016/j.jmir.2026.102292 |
|
2026 Journal Article Phase 2 expansion study of <sup>212</sup> Pb-ADVC001 in metastatic prostate cancer: The TheraPb trialHansen, Aaron Richard, Goh, Jeffrey C., Pattison, David A., Ngai, Stanley, Gan, Chun Loo Loo, Katchel, Loren, Brady, Jasmine, Kuchel, Anna, Latter, Melissa, Mason, Robert, Santoro, Paola, Crumbaker, Megan, Baronet, Meghan C., Grace, Reilly, Brilhante, Joana, Kryza, Thomas, Kuan, Kevin, Wiegert, Erol, Karmann, Anna and Wyld, David (2026). Phase 2 expansion study of 212 Pb-ADVC001 in metastatic prostate cancer: The TheraPb trial. Journal of Clinical Oncology, 44 (7_suppl). doi: 10.1200/jco.2026.44.7_suppl.tps280 |
|
2026 Journal Article A multicenter phase II randomized controlled trial comparing 177Lu-Dotatate/capecitabine combination treatment with 177Lu-Dotatate monotherapy in patients with neuroendocrine tumorsBecx, Morticia N., Hofland, Johannes, Krenning, Eric P., Wyld, David K., Nonnekens, Julie, Verburg, Frederik A., Brabander, Tessa, van Busschbach, Jan J.V. and de Herder, Wouter W. (2026). A multicenter phase II randomized controlled trial comparing 177Lu-Dotatate/capecitabine combination treatment with 177Lu-Dotatate monotherapy in patients with neuroendocrine tumors. Clinical Cancer Research, 32 (8), OF1-OF10. doi: 10.1158/1078-0432.ccr-25-1884 |
|
2025 Journal Article How to support participants in urogenital and prostate clinical trials: a qualitative perspectiveRoberts, Natasha A., Davis, Ian D., Wyld, David, Goh, Jeffrey, Thompson, Maxwell, Gedye, Craig and Dhillon, Haryana M. (2025). How to support participants in urogenital and prostate clinical trials: a qualitative perspective. Psycho-Oncology, 34 (7) e70214, 1-9. doi: 10.1002/pon.70214 |
|
2025 Journal Article Peptide receptor radionuclide therapy in malignant insulinomaPattison, David A., Kong, Grace, Akhurst, Timothy, Burge, Matthew, Chiang, Cherie, Hofman, Michael S., Hung, Te-Jui, Love, Amanda, Michael, Michael, Okano, Satomi, Ravi Kumar, Aravind S., Sachithanandan, Nirupa, Wyld, David and Hicks, Rodney J. (2025). Peptide receptor radionuclide therapy in malignant insulinoma. Endocrine-Related Cancer, 32 (6) e250018, 6. doi: 10.1530/erc-25-0018 |
|
2025 Journal Article Factors that influence clinical trial participation for oncology patients in Australia: a scoping reviewYou, Kyung Ha, Lwin, Zarnie, Ahern, Elizabeth, Wyld, David and Roberts, Natasha (2025). Factors that influence clinical trial participation for oncology patients in Australia: a scoping review. BMJ Open, 15 (6) e095355, 1-11. doi: 10.1136/bmjopen-2024-095355 |
|
2025 Journal Article Institutional factors associated with equitable cancer care provision for culturally and linguistically diverse populations in Queensland, Australia: a critical race theory analysisScanlon, Brighid, Roberts, Natasha, Wyld, David, Toloo, Ghasem Sam and Durham, Jo (2025). Institutional factors associated with equitable cancer care provision for culturally and linguistically diverse populations in Queensland, Australia: a critical race theory analysis. Journal of Racial and Ethnic Health Disparities, 1-15. doi: 10.1007/s40615-025-02477-8 |
|
2024 Journal Article Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancerWebb, Penelope M, Brown, Amy, Brown, Bena, Collins, Louisa G, Crawford Williams, Fiona, Doupain, Kerrie, Eastgate, Melissa, Fennelly, Vicki, Girgis, Afaf, Hartel, Gunter, Ladwa, Rahul, Martin, Karen, Mason, Robert, McGuire, Peter, Miller, Elizabeth, O’Brien, Suzanne, Packer, Rebecca, Pinkham, Mark B, Sabesan, Sabe, Sanmugarajah, Jasotha, Slapp, Georgia, Tapsall, Doreen, White, Jeanie, Wishart, Laurelie R, Wyld, David and Chan, Raymond J (2024). Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancer. BMJ Open, 14 (11) e090836, 1-10. doi: 10.1136/bmjopen-2024-090836 |
|
2024 Journal Article Implementation of Patient-Reported Outcomes in a Medical Oncology Setting (the iPROMOS Study): type II hybrid implementation studyRoberts, Natasha Anne, Pelecanos, Anita, Alexander, Kimberly, Wyld, David and Janda, Monika (2024). Implementation of Patient-Reported Outcomes in a Medical Oncology Setting (the iPROMOS Study): type II hybrid implementation study. Journal of Medical Internet Research, 26 e55841, e55841. doi: 10.2196/55841 |
|
2024 Journal Article Validity of patient-reported outcome measures in evaluating nerve damage following chemotherapyLi, Tiffany, Timmins, Hannah C., Mahfouz, Fawaz M., Trinh, Terry, Mizrahi, David, Horvath, Lisa G., Harrison, Michelle, Grimison, Peter, Friedlander, Michael, Marx, Gavin, Boyle, Frances, Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally, Kiernan, Matthew C., Rutherford, Claudia, Goldstein, David and Park, Susanna B. (2024). Validity of patient-reported outcome measures in evaluating nerve damage following chemotherapy. JAMA Network Open, 7 (8) e2424139, e2424139. doi: 10.1001/jamanetworkopen.2024.24139 |
|
2024 Journal Article Corrigendum to: COVID-19 vaccine hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional surveyScanlon, Brighid, Wyld, David, Firman, Paul, Nakagaki, Midori, Durham, Jo, Kennedy, Glen, Moran, Paul, Smith, Michael, Button, Elise and Gavin, Nicole (2024). Corrigendum to: COVID-19 vaccine hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional survey. Australian Health Review, 48 (3), 335-335. doi: 10.1071/ah22142_co |
|
2024 Journal Article Exploring unmet needs in prostate cancer care: a cross-sectional descriptive studyRoberts, Natasha A., Esler, Rachel, Pearce, Adam, Wyld, David, Smith, Michael, Woollett, Kaylene, Mazariego, Carolyn and Roberts, Matthew J. (2024). Exploring unmet needs in prostate cancer care: a cross-sectional descriptive study. European Urology Open Science, 62, 36-42. doi: 10.1016/j.euros.2024.01.018 |
|
2023 Journal Article Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRIArnfield, Evyn G., Tam, Laura, Pattison, David A., Younger, John, Chikatamarla, Venkata Avinash, Wyld, David, Burge, Matthew, McCormack, Louise, Ladwa, Rahul and Ramsay, Stuart (2023). Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI. Journal of Nuclear Cardiology, 30 (6), 2676-2691. doi: 10.1007/s12350-023-03345-w |
|
2023 Journal Article The unmet needs of pancreatic cancer carers are associated with anxiety and depression in patients and carersHuynh, Thi N. T., Hartel, Gunter, Janda, Monika, Wyld, David, Merrett, Neil, Gooden, Helen, Neale, Rachel E. and Beesley, Vanessa L. (2023). The unmet needs of pancreatic cancer carers are associated with anxiety and depression in patients and carers. Cancers, 15 (22) 5307, 1-12. doi: 10.3390/cancers15225307 |
|
2023 Journal Article The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosisGuccione, Lisa, Gough, Karla, Drosdowsky, Allison, Price, Timothy, Pavlakis, Nick, Wyld, David, Ransom, David, Michael, Michael and Schofield, Penelope (2023). The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis. Supportive Care in Cancer, 31 (10) 577, 1-11. doi: 10.1007/s00520-023-08034-5 |
|
2023 Journal Article Exploring equity in cancer treatment, survivorship, and service utilisation for culturally and linguistically diverse migrant populations living in Queensland, Australia: a retrospective cohort studyScanlon, Brighid, Durham, Jo, Wyld, David, Roberts, Natasha and Toloo, Ghasem Sam (2023). Exploring equity in cancer treatment, survivorship, and service utilisation for culturally and linguistically diverse migrant populations living in Queensland, Australia: a retrospective cohort study. International Journal for Equity in Health, 22 (1) 175, 1-10. doi: 10.1186/s12939-023-01957-9 |
|
2023 Journal Article Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancerLee, Shu Fen, Brown, Teresa, Wyld, David, Edwards, Anna and Eastgate, Melissa (2023). Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancer. Journal of Human Nutrition and Dietetics, 36 (3), 612-621. doi: 10.1111/jhn.13091 |
